RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Brazil: New criteria for priority drug review

Brazil: New criteria for priority drug review

Posted 04 April 2012 | By Ansis Helmanis

A public consultation on new criteria for prioritizing the review of drug approval applications is planned by Brazil's regulatory agency, ANVISA. 

The agency intends to propose a point system for determining which drugs should be "placed in front of the queue for review." 

According to the agency, an example of a marketing approval application that would get priority is for a generic version of a brand name drug that has no market competition. 

Read more:

ANVISA - Diretoria propõe novo critério para prioridades na fila de medicamentos

Regulatory Focus newsletters

All the biggest regulatory news and happenings.